

## HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use Toviaz safely and effectively. See full prescribing information for Toviaz.

**Toviaz® (fesoterodine fumarate)**

**For oral administration**

**Initial U.S. Approval: October 31, 2008**

### INDICATIONS AND USAGE

Toviaz is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. (1)

### DOSAGE AND ADMINISTRATION

The recommended starting dose of Toviaz is 4 mg once daily. Based upon individual response and tolerability, the dose may be increased to 8 mg once daily. (2)

The daily dose of Toviaz should not exceed 4 mg in the following populations:

- Patients with severe renal impairment ( $CL_{CR} < 30$  mL/min) (2)
- Patients taking potent CYP3A4 inhibitors, such as ketoconazole, itraconazole and clarithromycin. (2)

Toviaz is not recommended for use in patients with severe hepatic impairment (Child-Pugh C). (2)

Toviaz should be taken with liquid and swallowed whole. Toviaz can be administered with or without food, and should not be chewed, divided, or crushed. (2)

### DOSAGE FORMS AND STRENGTHS

Toviaz 4 mg extended-release tablets are light blue, oval, biconvex, film-coated and engraved with "FS" on one side. (3)

Toviaz 8 mg extended-release tablets are blue, oval, biconvex, film-coated and engraved with "FT" on one side. (3)

### CONTRAINDICATIONS

Toviaz is contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma. Toviaz is also contraindicated in patients with known hypersensitivity to the drug or its ingredients. (4)

### WARNINGS AND PRECAUTIONS

- Toviaz should be administered with caution to patients with clinically significant bladder outlet obstruction because of the risk of urinary retention. (5.1)
- Toviaz, like other antimuscarinic drugs, should be used with caution in patients with decreased gastrointestinal motility, such as those with severe constipation. (5.2)
- Toviaz should be used with caution in patients being treated for narrow-angle glaucoma, and only where the potential benefits outweigh the risks (5.3)

- Doses of Toviaz greater than 4 mg are not recommended in patients taking a potent CYP3A4 inhibitor (e.g. ketoconazole, itraconazole, clarithromycin).
- In patients taking weak or moderate CYP3A4 inhibitors (e.g. erythromycin), careful assessment of tolerability at the 4 mg daily dose is advised prior to increasing the daily dose to 8 mg. (5.6)

- Toviaz should be used with caution in patients with myasthenia gravis, a disease characterized by decreased cholinergic activity at the neuromuscular junction. (5.7)

### ADVERSE REACTIONS

The most frequently reported adverse events ( $\geq 4\%$ ) for Toviaz were: dry mouth (placebo, 7%; Toviaz 4 mg, 19%; Toviaz 8 mg, 35%) and constipation (placebo, 2%; Toviaz 4 mg, 4%; Toviaz 8 mg, 6%). (6)

**To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).**

### DRUG INTERACTIONS

- Doses of Toviaz greater than 4 mg are not recommended in patients taking potent CYP3A4 inhibitors. The effects of weak or moderate CYP3A4 inhibitors were not examined. (7.2)
- No dosing adjustments are recommended in the presence of CYP3A4 inducers or CYP2D6 inhibitors. (7.3, 7.4)
- There were no changes in the plasma concentrations of combined oral contraceptives containing ethinyl estradiol and levonorgestrel. (7.6)

### USE IN SPECIFIC POPULATIONS

- **Pregnancy and Nursing Mothers:** Toviaz should be used during pregnancy only if the potential benefit outweighs the potential risk to the fetus. (8.1)  
Toviaz should not be administered during nursing unless the potential benefit outweighs the potential risk to the neonate. (8.3)
- **Pediatric Use:** The safety and effectiveness of Toviaz in pediatric patients have not been established. (8.4)
- **Geriatric Use:** No dose adjustment is recommended for the elderly. (8.5)
- **Renal impairment:** Doses of Toviaz greater than 4 mg are not recommended in patients with severe renal impairment. (8.6)
- **Hepatic impairment:** Subjects with severe hepatic impairment (Child-Pugh C) have not been studied; therefore Toviaz is not recommended for use in these patients. (8.7)

**See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.**

Revised: [3/2010]

## FULL PRESCRIBING INFORMATION: CONTENTS\*

### 1 INDICATIONS AND USAGE

### 2 DOSAGE AND ADMINISTRATION

### 3 DOSAGE FORMS AND STRENGTHS

### 4 CONTRAINDICATIONS

### 5 WARNINGS AND PRECAUTIONS

- 5.1 Bladder Outlet Obstruction
- 5.2 Decreased Gastrointestinal Motility
- 5.3 Controlled Narrow-Angle Glaucoma
- 5.4 Hepatic Impairment
- 5.5 Renal Impairment
- 5.6 Concomitant Administration with CYP3A4 Inhibitors
- 5.7 Myasthenia Gravis

### 6 ADVERSE REACTIONS

### 7 DRUG INTERACTIONS

- 7.1 Antimuscarinic Drugs
- 7.2 CYP3A4 Inhibitors
- 7.3 CYP3A4 Inducers
- 7.4 CYP2D6 Inhibitors
- 7.5 Drugs metabolized by Cytochrome P450 Isoenzymes
- 7.6 Oral Contraceptives
- 7.7 Drug -Laboratory Test Interactions

### 8 USE IN SPECIFIC POPULATIONS

- 8.1 Pregnancy

- 8.3 Nursing Mothers

- 8.4 Pediatric Use

- 8.5 Geriatric Use

- 8.6 Renal Impairment

- 8.7 Hepatic Impairment

- 8.8 Gender

- 8.9 Race

### 10 OVERDOSAGE

### 11 DESCRIPTION

### 12 CLINICAL PHARMACOLOGY

- 12.1 Mechanism of Action

- 12.2 Pharmacodynamics

- 12.3 Pharmacokinetics

### 13 NONCLINICAL TOXICOLOGY

- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

### 14 CLINICAL STUDIES

### 16 HOW SUPPLIED/STORAGE AND HANDLING

### 17 PATIENT COUNSELING INFORMATION

- 17.1 Information for Patients

- 17.2 FDA Approved Patient Labeling

\*Sections or subsections omitted from the full prescribing information are not listed.

## FULL PRESCRIBING INFORMATION

### 1 INDICATIONS AND USAGE

Toviaz<sup>®</sup> is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.

### 2 DOSAGE AND ADMINISTRATION

The recommended starting dose of Toviaz is 4 mg once daily. Based upon individual response and tolerability, the dose may be increased to 8 mg once daily.

The daily dose of Toviaz should not exceed 4 mg in the following populations:

- Patients with severe renal impairment ( $CL_{CR} < 30$  mL/min).
- Patients taking potent CYP3A4 inhibitors, such as ketoconazole, itraconazole and clarithromycin.

Toviaz is not recommended for use in patients with severe hepatic impairment (Child-Pugh C) [*see WARNINGS AND PRECAUTIONS (5.4, 5.6, 5.7), USE IN SPECIFIC POPULATIONS (8.6, 8.7), and DRUG INTERACTIONS (7.2)*].

Toviaz should be taken with liquid and swallowed whole. Toviaz can be administered with or without food, and should not be chewed, divided, or crushed.

### 3 DOSAGE FORMS AND STRENGTHS

Toviaz (fesoterodine fumarate) extended-release tablets 4 mg are light blue, oval, biconvex, film-coated and engraved with “FS” on one side.

Toviaz (fesoterodine fumarate) extended-release tablets 8 mg are blue, oval, biconvex, film-coated and engraved with “FT” on one side.

### 4 CONTRAINDICATIONS

Toviaz is contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma. Toviaz is also contraindicated in patients with known hypersensitivity to the drug or its ingredients.

### 5 WARNINGS AND PRECAUTIONS

**5.1 Bladder Outlet Obstruction:** Toviaz should be administered with caution to patients with clinically significant bladder outlet obstruction because of the risk of urinary retention [*see CONTRAINDICATIONS (4)*].

**5.2 Decreased Gastrointestinal Motility:** Toviaz, like other antimuscarinic drugs, should be used with caution in patients with decreased gastrointestinal motility, such as those with severe constipation.

**5.3 Controlled Narrow-Angle Glaucoma:** Toviaz should be used with caution in patients being treated for narrow-angle glaucoma, and only where the potential benefits outweigh the risks [*see CONTRAINDICATIONS (4)*].

**5.4 Hepatic Impairment:** Toviaz has not been studied in patients with severe hepatic impairment and therefore is not recommended for use in this patient population [*see USE IN SPECIFIC POPULATIONS (8.7) and DOSAGE AND ADMINISTRATION (2)*].

**5.5 Renal Impairment:** Doses of Toviaz greater than 4 mg are not recommended in patients with severe renal impairment [*see USE IN SPECIFIC POPULATIONS (8.6) and DOSAGE AND ADMINISTRATION (2)*].

**5.6 Concomitant Administration with CYP3A4 Inhibitors:** Doses of Toviaz greater than 4 mg are not recommended in patients taking a potent CYP3A4 inhibitor (e.g. ketoconazole, itraconazole, clarithromycin).

In patients taking weak or moderate CYP3A4 inhibitors (e.g. erythromycin), careful assessment of tolerability at the 4 mg daily dose is advised prior to increasing the daily dose to 8 mg. While this specific interaction potential was not examined by clinical study, some pharmacokinetic interaction is expected, albeit less than that observed with potent CYP3A4 inhibitors [*see DRUG INTERACTIONS (7.2) and DOSAGE AND ADMINISTRATION (2)*].

**5.7 Myasthenia Gravis:** Toviaz should be used with caution in patients with myasthenia gravis, a disease characterized by decreased cholinergic activity at the neuromuscular junction.

## 6 ADVERSE REACTIONS

The safety of Toviaz was evaluated in Phase 2 and 3 controlled trials in a total of 2859 patients with overactive bladder of which 2288 were treated with fesoterodine. Of this total, 782 received Toviaz 4 mg/day, and 785 received Toviaz 8 mg/day in Phase 2 or 3 studies with treatment periods of 8 or 12 weeks. Approximately 80% of these patients had >10 weeks exposure to Toviaz in these trials.

A total of 1964 patients participated in two 12-week, Phase 3 efficacy and safety studies and subsequent open-label extension studies. In these 2 studies combined, 554 patients received Toviaz 4 mg/day and 566 patients received Toviaz 8 mg/day.

In Phase 2 and 3 placebo-controlled trials combined, the incidences of serious adverse events in patients receiving placebo, Toviaz 4 mg, and Toviaz 8 mg were 1.9%, 3.5%, and 2.9%, respectively. All serious adverse events were judged to be not related or unlikely to be related to study medication by the investigator, except for four patients receiving Toviaz who reported one serious adverse event each: angina, chest pain, gastroenteritis, and QT prolongation on ECG.

The most commonly reported adverse event in patients treated with Toviaz was dry mouth. The incidence of dry mouth was higher in those taking 8 mg/day (35%) and in those taking 4 mg/day (19%), as compared to placebo (7%). Dry mouth led to discontinuation in 0.4%, 0.4%, and 0.8% of patients receiving placebo, Toviaz 4 mg, and Toviaz 8 mg, respectively. For those patients who reported dry mouth, most had their first occurrence of the event within the first month of treatment.

The second most commonly reported adverse event was constipation. The incidence of constipation was 2% in

Table 3 lists adverse events, regardless of causality, that were reported in the combined Phase 3, randomized, placebo-controlled trials at an incidence greater than placebo and in 1% or more of patients treated with Toviaz 4 or 8 mg once daily for up to 12 weeks.

**Table 3 Adverse events with an incidence exceeding the placebo rate and reported by  $\geq 1\%$  of patients from double-blind, placebo-controlled Phase 3 trials of 12 weeks treatment duration**

System organ class/Preferred term	Placebo N=554 %	Toviaz 4mg/day N=554 %	Toviaz 8mg/day N=566 %
Gastrointestinal disorders			
Dry mouth	7.0	18.8	34.6
Constipation	2.0	4.2	6.0
Dyspepsia	0.5	1.6	2.3
Nausea	1.3	0.7	1.9
Abdominal pain upper	0.5	1.1	0.5
Infections			
Urinary tract infection	3.1	3.2	4.2
Upper respiratory tract infection	2.2	2.5	1.8
Eye disorders			
Dry eyes	0	1.4	3.7
Renal and urinary disorders			
Dysuria	0.7	1.3	1.6
Urinary retention	0.2	1.1	1.4
Respiratory disorders			
Cough	0.5	1.6	0.9
Dry Throat	0.4	0.9	2.3
General disorders			
Edema peripheral	0.7	0.7	1.2
Musculoskeletal disorders			
Back pain	0.4	2.0	0.9
Psychiatric disorders			
Insomnia	0.5	1.3	0.4
Investigations			
ALT increased	0.9	0.5	1.2
GGT increased	0.4	0.4	1.2
Skin disorders			
Rash	0.5	0.7	1.1

ALT=alanine aminotransferase, GGT=gamma glutamyltransferase

Patients also received Toviaz for up to three years in open-label extension phases of one Phase 2 and two Phase 3 controlled trials. In all open label trials combined, 857, 701, 529, and 105 patients received Toviaz for at least

studies were similar to those observed in the 12-week, placebo-controlled studies, and included dry mouth, constipation, dry eyes, dyspepsia and abdominal pain. Similar to the controlled studies, most adverse events of dry mouth and constipation were mild to moderate in intensity. Serious adverse events, judged to be at least possibly related to study medication by the investigator, and reported more than once during the open-label treatment period of up to 3 years included urinary retention (3 cases), diverticulitis (3 cases), constipation (2 cases), irritable bowel syndrome (2 cases), and electrocardiogram QT corrected interval prolongation (2 cases).

## 7 DRUG INTERACTIONS

**7.1 Antimuscarinic Drugs:** Coadministration of Toviaz with other antimuscarinic agents that produce dry mouth, constipation, urinary retention, and other anticholinergic pharmacological effects may increase the frequency and/or severity of such effects. Anticholinergic agents may potentially alter the absorption of some concomitantly administered drugs due to anticholinergic effects on gastrointestinal motility.

**7.2 CYP3A4 Inhibitors:** Doses of Toviaz greater than 4 mg are not recommended in patients taking potent CYP3A4 inhibitors, such as ketoconazole, itraconazole and clarithromycin. Coadministration of the potent CYP3A4 inhibitor ketoconazole with fesoterodine led to approximately a doubling of the maximum concentration ( $C_{max}$ ) and area under the concentration versus time curve (AUC) of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of fesoterodine. Compared with CYP2D6 extensive metabolizers not taking ketoconazole, further increases in the exposure to 5-HMT were observed in subjects who were CYP2D6 poor metabolizers taking ketoconazole [see *CLINICAL PHARMACOLOGY* (12.3), *WARNINGS AND PRECAUTIONS* (5.7) and *DOSAGE AND ADMINISTRATION* (2)].

The effects of weak or moderate CYP3A4 inhibitors were not examined.

**7.3 CYP3A4 Inducers:** No dosing adjustments are recommended in the presence of CYP3A4 inducers, such as rifampin and carbamazepine. Following induction of CYP3A4 by coadministration of rifampin 600 mg once a day,  $C_{max}$  and AUC of the active metabolite of fesoterodine decreased by approximately 70% and 75%, respectively, after oral administration of Toviaz 8 mg. The terminal half-life of the active metabolite was not changed.

**7.4 CYP2D6 Inhibitors:** The interaction with CYP2D6 inhibitors was not tested clinically. In poor metabolizers for CYP2D6, representing a maximum CYP2D6 inhibition,  $C_{max}$  and AUC of the active metabolite are increased 1.7- and 2-fold, respectively.

No dosing adjustments are recommended in the presence of CYP2D6 inhibitors.

**7.5 Drugs Metabolized by Cytochrome P450:** In vitro data indicate that at therapeutic concentrations, the active metabolite of fesoterodine does not have the potential to inhibit or induce Cytochrome P450 enzyme systems [see *CLINICAL PHARMACOLOGY* (12.3)]

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.